Cannabidiol

The CBSA gives tips for a smoother trip this Labour Day long weekend

Retrieved on: 
Tuesday, August 29, 2023
Weapon, AIRS, GPS, Travel, Directory, Arrest, Food, Atmosphere, Poultry, Service, Canadian Food Inspection Agency, Canada Border Services Agency, Firearm, CBSA, Plant, Google Maps, Labour, Animal, Influenza B virus, Oil, Agency, Child, Water, Cannabis, Letter, THC, Health Canada, Bird, Cannabidiol, Safety, Tourism, Drug, CBD, Waze

Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.

Key Points: 
  • Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.
  • The CBSA invests significant effort planning and preparing for peak periods, such as holiday long weekends and summer months.
  • For a smoother trip, you should:
    Plan ahead and check our border wait times web page.
  • The best thing you can do to save time is to be open and honest with the CBSA officer.

The CBSA gives tips for a smoother trip this Labour Day long weekend

Retrieved on: 
Tuesday, August 29, 2023
Weapon, AIRS, GPS, Travel, Directory, Arrest, Food, Atmosphere, Poultry, Service, Canadian Food Inspection Agency, Canada Border Services Agency, Firearm, CBSA, Plant, Google Maps, Labour, Animal, Influenza B virus, Oil, Agency, Child, Water, Cannabis, Letter, THC, Health Canada, Bird, Cannabidiol, Safety, Tourism, Drug, CBD, Waze

Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.

Key Points: 
  • Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.
  • The CBSA invests significant effort planning and preparing for peak periods, such as holiday long weekends and summer months.
  • For a smoother trip, you should:
    Plan ahead and check our border wait times web page.
  • The best thing you can do to save time is to be open and honest with the CBSA officer.

Paw CBD Recognized With “Dog Hip & Joint Product Of The Year” Award From Pet Innovation

Retrieved on: 
Thursday, August 17, 2023
Exercise, Pet, Hip, Retail, Service, Parent, Ageing, Taffy (candy), Inflammation, Dicarboxylic acid, Chondroitin sulfate, Dog, Superior, THC, NYSE, Food, Cannabidiol, Health, Housing, CBD

Paw CBD Hip+Joint Soft Chews provide extra comfort and care for dogs in order to support mobility and enhance comfort.

Key Points: 
  • Paw CBD Hip+Joint Soft Chews provide extra comfort and care for dogs in order to support mobility and enhance comfort.
  • Paw CBD’s NASC certified Hip+Joint Chews come in a bacon flavor, and the soft texture makes it ideal for small, aging, or sensitive teeth.
  • “We’re so excited to be recognized with the ‘Dog Hip & Joint Product of the Year’ award from Pet Innovation.
  • PawCBD offers a product that makes every day happy, healthy, and comfortable for pets,” said Travis Grant, Managing Director, Independent Innovation Awards.

VPR Brands Announces Q2 2023 and Year to Date Financial Results 

Retrieved on: 
Wednesday, August 16, 2023
Intellectual property, Nicotine, Lighter, ELF, Sale, Date, OTC, Cannabis, Cannabidiol, Three Months, IBN, Cryptocurrency, Beauty salon, CBD

Results of Operations for the Three Months Ended June 30, 2023, Compared to the Three Months Ended June 30, 2022

Key Points: 
  • Results of Operations for the Three Months Ended June 30, 2023, Compared to the Three Months Ended June 30, 2022
    Our revenues for the three months ended June 30, 2023, and 2022 were $1,909,529 and $920,705, respectively.
  • Net income for the three months ended June 30, 2023, was $928,322 compared to $73,733 for the three months ended June 30, 2022.
  • Results of Operations for the Six Months Ended June 30, 2023, Compared to the Six Months Ended June 30, 2022
    Our revenues for the six months ended June 30, 2023, and 2022 were $4,990,550 and $1,975,937, respectively.
  • Net income for the six months ended June 30, 2023, was $953,636 compared to a net loss of ($73,508) for the six months ended June 30, 2022.

22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
VLN, Nicotine, Table, Marketing, GVB, Research, Tobacco, Commencement (album), Pacific Century Group, CBG, Sale, Fourth, Old pal, Investment, Cost, Pinnacle, Webcast, XXII, Growth, Century, Health, FDA, Biomass, Letter, Adjustment, Second, Cannabidiol, Drug, Video game, Pharmaceutical industry, Retail, Whaling, Natural gas, Management, Tourism, Rare-earth element, CBD

Net revenues for the second quarter of 2023 were $23.4 million, an increase of 61.8% from the same period in 2022.

Key Points: 
  • Net revenues for the second quarter of 2023 were $23.4 million, an increase of 61.8% from the same period in 2022.
  • Gross profit for the second quarter of 2023 was $(2.3) million as compared to $0.9 million in the prior year period.
  • Gross margin is expected to improve in the second half of 2023 reflecting:
    New CDMO+D contracts to begin shipping product in the second half of 2023.
  • to discuss its second quarter 2023 financial results and business highlights.

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

Retrieved on: 
Tuesday, August 15, 2023
Technology, Health Technology, Software, Biotechnology, Other Health, Health, Pharmaceutical, Data Management, Artificial Intelligence, Seizure, Drug development, SLP, Clinical Pharmacology & Therapeutics, Lennox–Gastaut syndrome, Simulations Plus, QST, Chapel Hill, Liver injury, Dravet syndrome, Risk, Hepatotoxicity, Drug design, Incidence, Patient, Manuscript, University, History of the University of North Carolina at Chapel Hill, ALT, FDA, Therapy, VPA, Cannabidiol, Safety, Medical device, Dietary supplement, Pharmaceutical industry, CBD

CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Key Points: 
  • CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
  • During the pre-approval clinical trials, treatment with CBD was occasionally associated with elevation in blood levels of ALT, a marker of liver injury, but this was much more common in patients already receiving treatment with VPA for seizures.
  • To identify potential underlying mechanisms, researchers used DILIsym to predict ALT levels in simulated populations that were treated with CBD alone, treated with VPA alone, and then treated with VPA before they were treated with CBD.
  • DILIsym predicted dose-dependent ALT elevations for CBD treatment and ALT elevations for VPA treatment when each was given alone, but the combined VPA and CBD treatment protocol mimicking the clinical trials did not increase the incidence of ALT elevations relative to CBD treatment on its own.

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Diabetic neuropathy, Allodynia, Weight loss, Disclosure, Cancer, Research, CIPN, Pain, Patient, Investment, FDA, Cannabidiol, Pharmaceutical industry, Vaccine, Cryptocurrency, CBD

SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended June 30, 2023 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended June 30, 2023 and provided a business update.
  • “During the second quarter we were pleased to announce the achievement of multiple objectives and present new data,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • “With approximately $14.0 million in cash and investments as of June 30, 2023, we believe we have the financial resources to support operations into the second half of 2024.
  • Financial Results Ended June 30, 2023
    Operating expenses for the three months ended June 30, 2023, were $1.8 million compared to $2.5 million for the same period in 2022.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

Retrieved on: 
Tuesday, August 8, 2023
Temple University, Drug discovery, Head, University of Bristol, Merck, Commercial Operating System, Biotechnology Innovation Organization, Otsuka Pharmaceutical, BIO, University, Ōtsuka, GW, Honours degree, GW Pharmaceuticals, Genetic distance, Corcept Therapeutics, Organization, UCB, Villalba v Merrill Lynch & Co Inc, Cannabidiol, Mazda North American Operations, Drexel University, Epilepsy, Neuroscience, INSEAD, Justin, Roivant Sciences, Therapy, Doctor of Philosophy, Sale, Defense Innovation Board, DSM-IV codes, Jazz Pharmaceuticals, University of Edinburgh, Pharmaceutical industry, Xenon

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “On behalf of our Board of Directors, I am delighted to welcome Gillian and Justin to our Board.
  • Gillian brings a vast knowledge of commercializing novel medicines and leading successful neuroscience franchises at large pharmaceutical companies.
  • Mr. Gover currently serves on the Board of Directors for CURE Epilepsy and Rady Children’s Institute for Genomic Medicine.

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

Retrieved on: 
Monday, August 7, 2023
Epilepsy, Volunteering, PK, Rat, Hadassah Medical Center, PNL, Al-Quds, Hebrew University of Jerusalem, Mouth, Obesity, TNF, Delirium, Gastrointestinal tract, PALO, Anxiety, Injury, Pharmacokinetics, American Academy, Absorption, Antibody, Pain, Fibrosis, Necrosis, MD, Post-traumatic stress disorder, Patient, Blood, School, Pharmacy school, Cannabidiol, FDA, Hand, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, PTSD, Rheumatoid arthritis, Pharmaceutical industry, Pharmacy, CBD

The PK study will seek to determine how much CBD is taken up into the blood of volunteers.

Key Points: 
  • The PK study will seek to determine how much CBD is taken up into the blood of volunteers.
  • The dosage form has been shown in preliminary testing in rats to increase uptake of CBD, decrease absorption variability and enable controlled release pharmacokinetics.
  • Based on these animal results, a human PK study is being designed to test whether the formulation increases CBD blood levels after oral administration.
  • The currently available plant-based CBD formulations may contain up to 100 compounds and not just the CBD molecule.

The CBSA gives tips for a smoother trip this August long weekend

Retrieved on: 
Wednesday, August 2, 2023
Weapon, AIRS, GPS, Travel, Directory, Arrest, Food, Atmosphere, Poultry, Service, Canadian Food Inspection Agency, Canada Border Services Agency, Firearm, CBSA, Plant, Google Maps, Animal, Influenza B virus, Oil, Agency, Child, Water, Cannabis, Letter, THC, Health Canada, Bird, Cannabidiol, Safety, Drug, CBD, Waze

Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.

Key Points: 
  • Over the Canada Day long weekend, our officers welcomed more than one million travellers while keeping wait times to a minimum.
  • The CBSA invests significant effort planning and preparing for peak periods, such as holiday long weekends and summer months.
  • For a smoother trip, you should:
    Plan ahead and check our border wait times web page.
  • The best thing you can do to save time is to be open and honest with the CBSA officer.